Actively Recruiting
VENTURI (VENTilation Using Respiratory Imaging)
Led by University of Alabama at Birmingham · Updated on 2026-04-13
20
Participants Needed
1
Research Sites
250 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to enroll participants with uncontrolled asthma to evaluate the large and small airways and drug delivery utilizing two study drugs: * Beclometasone dipropionate/Formoterol fumarate dihydrate/Glycopyrronium bromide (BDP/FF/G) or Trimbow * Fluticasone furoate/Umeclidinium/Vilanterol (FluF/UMEC/VI ) or Trelegy Ellipta
CONDITIONS
Official Title
VENTURI (VENTilation Using Respiratory Imaging)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided written informed consent before any study procedures
- Aged 18 to 75 years
- Confirmed asthma diagnosis for at least 1 year with diagnosis before age 40 or pre-bronchodilator FEV1 between 50-80% predicted
- Symptomatic despite ICS/LABA treatment with ACT score below 20
- No asthma exacerbations requiring systemic corticosteroids or hospital visit in past 3 months
- Able to be trained and correctly use both pMDI and DPI inhalers
- Cooperative and able to perform required lung function tests and understand risks
- Women of childbearing potential (WOCBP) must use effective contraception or have non-fertile male partners
- Female patients not able to become pregnant (post-menopausal or permanently sterile)
You will not qualify if you...
- Pregnant or breastfeeding women
- Asthma exacerbation requiring systemic steroids or hospitalization within 3 months before screening
- Unable to perform lung function tests or comply with study procedures or treatments
- History of near-fatal asthma or ICU hospitalization for asthma posing undue risk
- Use of systemic corticosteroids within 4 weeks or slow-release corticosteroids within 12 weeks before screening
- Diagnosis of COPD or other significant lung diseases like cystic fibrosis, bronchiectasis, or alpha-1 antitrypsin deficiency
- Current smokers, e-cigarette users, or ex-smokers with 10 or more pack-years or quit within 1 year
- Significant cardiovascular conditions such as congestive heart failure (NYHA class >2), recent ischemic heart disease, serious arrhythmias, or conduction blocks
- Unable to undergo CT or MRI imaging or intolerant to Xenon gas
- Participation in another therapeutic trial within past 6 months
- Allergy to milk protein
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
Actively Recruiting
Research Team
E
Elizabeth Plan, RRT
CONTACT
S
Surya Bhatt, MD, MSPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here